Radiation Dosimetry and Biodistribution of


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
08 2020
Historique:
received: 18 09 2019
accepted: 02 12 2019
pubmed: 15 12 2019
medline: 30 12 2020
entrez: 15 12 2019
Statut: ppublish

Résumé

Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic imaging and therapy because they can constitute as much as 90% of a tumor mass. The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target. The quinoline-based FAP inhibitor (FAPI) PET tracer

Identifiants

pubmed: 31836685
pii: jnumed.119.236786
doi: 10.2967/jnumed.119.236786
pmc: PMC7413240
doi:

Substances chimiques

68Ga-FAPI 0
Quinolines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1171-1177

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Mol Cancer Ther. 2012 Feb;11(2):257-66
pubmed: 22323494
Radiology. 2009 Apr;251(1):166-74
pubmed: 19251940
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
J Nucl Med. 2013 Oct;54(10):1755-9
pubmed: 23929824
Mol Med Rep. 2015 May;11(5):3203-11
pubmed: 25593080
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
PLoS One. 2015 Mar 16;10(3):e0116683
pubmed: 25775399
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1962-70
pubmed: 27207281
Oncogene. 2018 Aug;37(32):4343-4357
pubmed: 29720723
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2456-2474
pubmed: 30218316
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Int J Mol Med. 2018 Jan;41(1):275-283
pubmed: 29115573
BMC Cancer. 2018 Nov 12;18(1):1099
pubmed: 30419872
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
pubmed: 2402505
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Nat Med. 2011 Nov 07;17(11):1359-70
pubmed: 22064426
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2569-2580
pubmed: 31388723
Cancer Biol Ther. 2014 Oct;15(10):1413-22
pubmed: 25046247
Proteomics Clin Appl. 2014 Jun;8(5-6):454-63
pubmed: 24470260
FEBS Open Bio. 2013 Dec 08;4:43-54
pubmed: 24371721
Ann ICRP. 1991;21(1-3):1-201
pubmed: 2053748
Cancers (Basel). 2019 Mar 06;11(3):
pubmed: 30845711
Pathol Oncol Res. 2019 Jan;25(1):369-376
pubmed: 29134462
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1238-50
pubmed: 20411259
Protoplasma. 2018 Jan;255(1):375-386
pubmed: 28620698
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1611-20
pubmed: 27260521
J Nucl Med. 2018 Oct;59(10):1494-1499
pubmed: 30002109
J Nucl Med. 2009 Mar;50(3):477-84
pubmed: 19258258
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1754-1755
pubmed: 31119317
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978805

Auteurs

Catherine Meyer (C)

Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Magnus Dahlbom (M)

Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Thomas Lindner (T)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Sebastien Vauclin (S)

DOSIsoft SA, Cachan, France.

Christine Mona (C)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Roger Slavik (R)

Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Institute of Urologic Oncology, UCLA, Los Angeles, California.
Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and.

Uwe Haberkorn (U)

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and.
Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.

Jeremie Calais (J)

Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California jcalais@mednet.ucla.edu.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
Institute of Urologic Oncology, UCLA, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH